Skip to main content

Julie A. Kreyenbuhl, PharmD, PhD

Academic Title:

Professor

Primary Appointment:

Psychiatry

Additional Title:

Associate Director, Research Core, VA VISN 5 Mental Illness Research, Education, and Clinical Center (MIRECC)

Location:

VA Annex, 735

Phone (Primary):

410-637-1864

Phone (Secondary):

410-706-3211

Fax:

410-637-1880

Education and Training

Education

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  • Mercer University College of Pharmacy (Magna cum laude), Pharm.D., 1993
  • University of Maryland School of Pharmacy, Ph.D., 1999

 

 

Post Graduate Education and Training

 

 

 

 

 

 

 

 

 

 

 

  • Post-doctoral fellowship, Maryland Psychiatric Research Center, University of Maryland School of Medicine, 2000

Biosketch

Dr. Kreyenbuhl’s primary research interest is the pharmacoepidemiology of serious mental illness (SMI). She has been the recipient of multiple grants from the NIH, VA, and private foundations in this area. She has contributed extensively to the development of evidence-based treatment guidelines for schizophrenia, serving as a co-investigator on the first update and principal investigator of grants funded by the NIMH and the VA to support the second update of the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. She has also served as the PI, Co-PI, or Co-I on local and federally funded efforts to study computer-technology based interventions for individuals with SMI, including the development and testing of a Smartphone application for enhancing adherence to antipsychotic medications. She has also received grant funding from VA HSR&D to develop an intervention to increase screening for the metabolic side effects of antipsychotic medications and to study how women Veterans with serious mental illnesses and their prescribers manage these side effects that are particularly distressing to women. She also has extensive experience using large administrative health services utilization databases for research. She has received support from the Stanley Medical Research Institute to use VA administrative data to identify novel non-psychotropic pharmacologic targets for the treatment of schizophrenia and bipolar disorder and to conduct comparative effectiveness analyses of antipsychotics in these populations. She has also used VA administrative data to investigate persistence of antipsychotic treatment in veterans with schizophrenia and adherence to hypoglycemic medications in veterans with and without schizophrenia. Her most current work involves using the 50-state Medicaid Analytic extracts and Medicare Part D administrative data to study expansion of advanced practice registered nurses’ prescriptive authority as one approach to addressing the significant psychiatrist-prescriber workforce shortage in the U.S.. Dr. Kreyenbuhl has authored or co-authored over 90 publications in peer-reviewed journals.

Research/Clinical Keywords

serious mental illness; health services research; pharmacoepidemiology

Highlighted Publications

Weiser M, Davis J, Brown CH, Slade EP, Fang L, Medoff DR, Buchanan RW, Levi L, Davidson M, Kreyenbuhl J. Differences in antipsychotic treatment discontinuation among veterans with schizophrenia in the U.S. Department of Veterans Affairs. American Journal of Psychiatry. 2021 Jul 14:appiajp202020111657. doi: 10.1176/appi.ajp.2020.20111657. Epub ahead of print. PMID: 34256606.

Kreyenbuhl J, Dixon LB, Brown CH, Medoff DR, Klingaman EA, Fang L, Tapscott S, Walsh M. A Randomized Controlled Trial of a Patient-Centered Approach to Improve Screening for the Metabolic Side Effects of Antipsychotic Medications.  Community Mental Health Journal 2016 Apr 9. [Epub ahead of print] PubMed PMID: 27061185.

Kreyenbuhl J, Medoff DR, McEvoy JP, Smith TE, Hackman A, Nossel IR, Dixon LB, Essock SM, Buchanan RW. The RAISE Connection Program: Psychopharmacological Treatment of People with a First Episode of Schizophrenia. Psychiatric Services; 2016 Jul 1:appips201500438. [Epub ahead of print] PubMed PMID: 27364816.

Kreyenbuhl J, Record EJ, Palmer-Bacon J. A Review of Behavioral Tailoring Strategies for Improving Medication Adherence in Serious Mental Illness. Dialogues in Clinical Neuroscience 2016 Jun;18(2):191-201.

Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB.  The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009. Schizophr Bull 2010 Jan; 36(1):94-103.

Additional Publication Citations

×